Commission Cap Powers Under the Sabka Bima Act: Scenario Planning for Broker P&Ls in 2026

The Sabka Bima Sabki Raksha (Amendment of Insurance Laws) Act, 2025, in force from 5 February 2026, is best known among brokers for perpetual intermediary licences, composite licences, and the opening to 100 percent FDI in intermediaries. Buried in the same statute is the provision with the largest potential P&L effect: the restoration of IRDAI's statutory power to cap distributor commissions.

Recall the sequence. Before April 2023, the Insurance Act read with IRDAI regulations imposed product-wise commission caps: fixed maximum percentages by line and product. The IRDAI (Payment of Commission) Regulations, 2023 swept those away, leaving commission to each insurer's board-approved policy, constrained only at the aggregate level by the IRDAI (Expenses of Management, including Commission, of Insurers) Regulations, 2024: roughly 30 percent of gross written premium for general insurers and 35 percent for standalone health insurers. For three years, the rate on any given placement has been a commercial negotiation inside that envelope.

The 2025 Act restores the legal machinery to reverse that. It does not itself impose any cap; it re-arms the regulator with explicit statutory authority to prescribe limits on commission and remuneration, together with the manner of payment and disclosure. A power on the statute book is not a rule in force, and IRDAI may leave it dormant. But powers restored by Parliament after being deliberately removed are rarely restored for decoration, and July 2026 reporting that IRDAI plans a commission overhaul consultation, with caps by product type, tenure, and complexity under discussion, suggests the regulator is actively considering when and how to use it.

For a broking board, the correct posture is neither alarm nor denial. It is scenario planning: define the plausible futures, quantify each against your own book, and identify the early signals that tell you which future is arriving.

Nobody outside IRDAI knows whether, when, or in what form caps return. Prediction is a coin toss; preparation is not. The scenario method suits this problem for three reasons.

First, the outcome space is genuinely discrete. Commission regimes come in recognisable shapes: an aggregate-only envelope (the status quo), line-wise rate caps (the pre-2023 shape), and structure-based rules keyed to tenure and payout timing (the shape the 2026 consultation discussion points toward). Modelling three shapes covers most of the probability mass.

Second, the inputs are already in the firm's systems. Commission income by line, by insurer, by product, and by payout timing is extractable from any competently maintained broking ledger, and firms preparing for the June 2026 draft intermediary disclosure regulations are building exactly this decomposition anyway. The marginal cost of scenario modelling on top of that data work is small.

Third, the decisions the scenarios inform are slow decisions. Diversifying revenue toward fees, rebalancing the book across lines, building working-capital headroom, and repricing servicing take four to eight quarters to execute. A firm that starts when the final rule is gazetted has already lost the adjustment window; transition periods in Indian insurance regulation are typically 12 months or less.

The discipline that makes the exercise useful: model your actual book, not the industry average. A marine and engineering specialist and a retail-health-heavy platform broker face wildly different exposure under identical rules. Segment the revenue base first (by line, by product tenure, by current realised yield against any plausible cap level), then run each scenario against those segments.

In the first scenario, IRDAI leaves the restored power dormant. The 2023 deregulation stands, commission remains a board-approved insurer decision, and the only ceiling is the insurer-level EOM envelope. The 2026 consultation, in this scenario, ends in disclosure tightening rather than rate intervention.

This is not a no-change scenario for broker economics; it is a continuation of slow compression. The EOM ceilings bite at the insurer level, and insurers under expense pressure keep rationalising commission schedules, trimming reward-and-recognition programmes, and reallocating budget across channels. Realised broker yields drift down one to two percentage points over a planning horizon without any new rule being made. Firms saw exactly this through FY2024-25 and FY2025-26.

P&L effect on a composite mid-tier commercial broker (INR 300 crore premium handled, INR 36 crore revenue, INR 9 crore EBITDA): revenue erodes perhaps 3 to 6 percent over two years, absorbable through normal productivity gains. The strategic risk in this scenario is complacency, because the same period will bring the disclosure regime (audited revenue schedules filed by 30 September and published on the broker's website, if the June 2026 draft is notified substantially as proposed), and public revenue data changes client negotiation even when rates are legally free.

Probability weighting is a board judgment, but the signals that keep you in this scenario are: a 2026 consultation paper focused on disclosure and conduct rather than rates, no draft regulations invoking the new commission-limit power within 12 to 18 months of the Act's commencement, and IRDAI public statements continuing to emphasise the EOM envelope as the primary discipline.

In the second scenario, IRDAI uses the restored power to prescribe maximum commission rates by line: a return to the pre-2023 architecture, presumably at levels informed by three years of observed board-approved rates and the mis-selling record. The 2026 discussion of caps differentiated by product type and complexity is a variant of this shape.

The P&L effect depends entirely on where your current realised yields sit relative to plausible cap levels, which is why the book segmentation matters. Work the composite broker again, with segments:

• Large-risk commercial property and engineering (INR 120 crore premium at 8 to 10 percent realised): plausible caps would likely sit at or above current realised rates, because large-risk placement rates were never the mis-selling concern. Impact near zero.
• Mid-market package and SME lines (INR 100 crore at 12 to 15 percent): a cap pitched around historical schedules could shave 1 to 3 percentage points of yield. Revenue impact INR 1 to 3 crore.
• Retail health and miscellaneous retail (INR 80 crore at 15 to 20 percent, including variable components): the segment regulators associate with excess. A cap regime targeting retail could compress yields 3 to 6 percentage points. Revenue impact INR 2.5 to 5 crore.

Aggregate: revenue down INR 4 to 8 crore on INR 36 crore, EBITDA down 40 to 80 percent before response. The response levers, in order of speed: renegotiate servicing scope with insurers (caps limit commission, not separately contracted service fees, subject to how anti-avoidance drafting treats them), reprice client-side fees on advisory-heavy accounts, shift mix toward segments where the firm's yield sits below cap, and cut acquisition-side cost that the capped economics no longer carry.

The signals for this scenario: the consultation paper carrying a schedule-style annexure of rates by product, IRDAI citing observed commission levels as evidence, and insurer CFO commentary welcoming rate certainty. Note one second-order effect: line-wise caps flatten the negotiating advantage of large brokers, whose scale currently extracts above-market rates, and relatively improve the position of smaller firms already earning at or below cap levels.

The third scenario is the most novel and, on the July 2026 signals, increasingly plausible: rules that regulate the shape of commission rather than only its level. Staggered or trail payment spread over the policy's life instead of upfront concentrations (which reach roughly 40 percent of premium on some life and health products), possibly combined with effort-based differentiation that pays more for advisory and claims servicing than for passive distribution.

For annual commercial lines, tenure rules change little: the policy renews yearly and commission already recurs. The exposure concentrates in three places on a broker's book:

1. Long-tenure retail products (multi-year health, life-adjacent placements): upfront income restructures into trails. Total remuneration on persistent policies may be preserved, but year-one cash on new business can halve, creating a 12 to 24 month working-capital gap for growing firms.
2. Group and credit-linked business with thin servicing: effort-based differentiation would move these toward the bottom of the remuneration scale.
3. High-growth retail verticals: the faster the new-business engine runs, the larger the financing gap a trail regime creates, because acquisition cost is paid today against income arriving over five years.

P&L effect on the composite broker: the commercial 60 percent of the book is broadly unaffected; the retail 40 percent sees a transition-period revenue dip of 30 to 50 percent on new business, netting to a firm-level revenue dip of 10 to 20 percent for one to two years, then recovery on stacked trails with better-quality earnings (recurring, persistency-linked, valuable in M&A). The management problem is bridge financing and cost phasing rather than permanent impairment, provided persistency holds. Firms with weak renewal retention discover in this scenario that their historical earnings overstated their real economics.

Signals: the end-July 2026 consultation paper leading with trail and effort-based design, IRDAI conduct commentary linking upfront payouts to mis-selling data, and any pilot framework applied first to life or health products.

Turning the scenarios into a working tool takes one focused quarter and no exotic tooling.

The model. Start from three financial years of commission income decomposed by line, product tenure, insurer, and payout timing. Overlay each scenario as a yield or timing transformation on each segment: status quo as a 50 to 150 basis-point drift, line caps as segment-wise rate ceilings at two or three assumed levels, structure rules as an upfront-to-trail conversion with your actual persistency rates. Output three numbers per scenario: revenue impact at steady state, worst transition-year EBITDA, and peak working-capital need. Present all nine to the board with the response levers priced against each.

The dashboard. Assign someone, typically the compliance head, to track five observable indicators quarterly:

1. The content and drafting shape of the expected end-July 2026 consultation paper, once published.
2. Whether draft regulations invoking the restored commission-limit power appear, and their scope (life only, health, or all lines).
3. EOM enforcement posture: forbearance versus glide-path pressure on insurers, which drives the status quo compression rate.
4. Progress of the June 2026 draft intermediary disclosure regulations to final form, since audited public revenue data feeds any future rate-setting.
5. Insurer behaviour: unilateral commission schedule revisions and reward-programme changes, which often front-run regulation.

The hedges that pay in every scenario. Some moves are scenario-proof and should start now regardless of the dashboard: growing fee income on advisory-heavy accounts (fee revenue sits outside any commission cap), lifting renewal retention (it is the revenue base under trails and the persistency evidence in any consultation), documenting servicing effort (the qualifying record for effort-based tiers), and holding or arranging working capital equal to at least one quarter of retail commission income. A firm that has done these four things can read whichever final rule arrives as an operating adjustment rather than an existential event.